Literature DB >> 14683466

Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders.

Martyn D Wood1.   

Abstract

Anxiety disorders are the most common psychiatric illness affecting both adults and children. Following the observation that m-chlorophenylpiperazine(mCPP) induced anxiety-like states in patients and in animal models, it was shown that in man, mCPP behaves as a functionally selective agonist at the 5-hydroxytryptamine (5-HT)2C receptor. This caused much interest in the development of antagonists at the 5-HT2C receptor for the treatment of anxiety disorders. This review examines the pre-clinical and clinical evidence for a role of the 5-HT2C receptor in anxiety and evaluates the progress of compounds that target this therapeutic approach.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14683466     DOI： 10.2174/1568007033482698

Source DB:  PubMed          Journal:  Curr Drug Targets CNS Neurol Disord        ISSN： 1568-007X


  10 in total

1.  The role of serotonin-2 (5-HT2) and dopamine receptors in the behavioral actions of the 5-HT2A/2C agonist, DOI, and putative 5-HT2C inverse agonist, SR46349B.

Authors:  Laura C Scarlota; John A Harvey; Vincent J Aloyo
Journal:  Psychopharmacology (Berl)       Date:  2010-07-21       Impact factor: 4.530

2.  Behavioral effects of systemically administered MK-212 are prevented by ritanserin microinfusion into the basolateral amygdala of rats exposed to the elevated plus-maze.

Authors:  Antonio Pedro de Mello Cruz; Gilson Pinheiro; Sérgio Henrique Alves; Graziela Ferreira; Marília Mendes; Letícia Faria; Carlos Eduardo Macedo; Vitor Motta; J Landeira-Fernandez
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

3.  A 5-HT(2C) receptor antagonist potentiates a low dose amphetamine-induced conditioned place preference.

Authors:  John D McCorvy; Aubrie A Harland; Rebecca Maglathlin; David E Nichols
Journal:  Neurosci Lett       Date:  2011-07-30       Impact factor: 3.046

4.  Reduction in repeated ethanol-withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT1A and 5-HT2C ligands.

Authors:  David H Overstreet; Darin J Knapp; Robert A Angel; Montserrat Navarro; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2006-05-19       Impact factor: 4.530

5.  Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis.

Authors:  Sheng-Min Wang; Young Sup Woo; Nak-Young Kim; Hae-Ran Na; Hyun Kook Lim; Won-Myong Bahk
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-08-31       Impact factor: 2.582

6.  5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats.

Authors:  Peter Salchner; Nicolas Singewald
Journal:  Psychopharmacology (Berl)       Date:  2006-03-07       Impact factor: 4.530

7.  Behavioral Effects of Systemic, Infralimbic and Prelimbic Injections of a Serotonin 5-HT2A Antagonist in Carioca High- and Low-Conditioned Freezing Rats.

Authors:  Laura A León; Vitor Castro-Gomes; Santiago Zárate-Guerrero; Karen Corredor; Antonio P Mello Cruz; Marcus L Brandão; Fernando P Cardenas; J Landeira-Fernandez
Journal:  Front Behav Neurosci       Date:  2017-07-07       Impact factor: 3.558

Review 8.  Serotonin and brain function: a tale of two receptors.

Authors:  R L Carhart-Harris; D J Nutt
Journal:  J Psychopharmacol       Date:  2017-08-31       Impact factor: 4.153

9.  Genotype-Dependent Difference in 5-HT2C Receptor-Induced Hypolocomotion: Comparison with 5-HT2A Receptor Functional Activity.

Authors:  Darya V Bazovkina; Elena M Kondaurova; Vladimir S Naumenko; Evgeni Ponimaskin
Journal:  Neural Plast       Date:  2015-08-26       Impact factor: 3.599

Review 10.  The vital role of constitutive GPCR activity in the mesolimbic dopamine system.

Authors:  F J Meye; G M J Ramakers; R A H Adan
Journal:  Transl Psychiatry       Date:  2014-02-11       Impact factor: 6.222
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.